Saeed Motahari insider trades: Insys Therapeutics (INSY) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Saeed reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 10, 2017 | INSY | ↑ Buy | 5,500 | $8.92 | $49K | Direct | Aug 10, 2017 (0d) |
| Jun 14, 2017 | INSY | ↑ Buy | 5,400 | $11.10 | $60K | Direct | Jun 14, 2017 (0d) |
| May 16, 2017 | INSY | ↑ Buy | 4,500 | $11.98 | $54K | Direct | May 16, 2017 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Saeed Motahari's insider trades
Saeed Motahari is President & CEO at Insys Therapeutics (INSY). Since May 16, 2017, Saeed has reported 3 open-market purchases worth $163K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INSY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.